CVnCoV Vaccine (CureVac)

Acquisition aims to strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech’s next milestone in the execution of its oncology strategy 收购旨在加强基于mRNA的癌症免疫治疗候选药物的研究、开发、制造和商业化，标志着BioNTech在其肿瘤学战略执行中的下一个里程碑。CureVac shareholders receive approximately $5.46 in BioNTech American Depositary Shares for each CureVac share, subject to a collar; an indicative exchange ratio will be availabl CureVac股东每持有一股CureVac股票，将获得大约5.46美元的BioNTech美国存托股份，具体视乎限制条件；指示性兑换比率将会提供。e at 在www.envisionreports.com/CureVacOffer www.envisionreports.com/CureVacOfferfor the duration of the exchange offer 在交换要约期间Information on how CureVac shareholders can participate in the exchange offer is available via Georgeson LLC, the information agent for the exchange offer, at +1 888 686 7195 (toll free in the US), +1 732 353 1948 (collect), or CureVac股东如何参与交换要约的信息可通过交换要约的信息代理Georgeson LLC获取，电话为+1 888 686 7195（美国免费），+1 732 353 1948（对方付费），或Curevacoffer@georgeson.com Curevacoffer@georgeson.comExchange offer will expire at 9:00 a.m. (New York City time) on December 3, 2025, unless extended or terminated earlier, in accordance with the terms of the Purchase Agreement 交换要约将于2025年12月3日上午9:00（纽约市时间）到期，除非根据购买协议的条款提前延长或终止。MAINZ, Germany, October 22, 2025 (GLOBE NEWSWIRE) 德国美因茨，2025年10月22日（环球新闻社）-- --BioNTech SE BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced it had commenced its public exchange offer (the “Offer”) for all outstanding shares of CureVac N.V. (Nasdaq: CVAC, “CureVac”). The Offer is being made pursuant to the previously announced purchase agreement between BioNTech and CureVac, dated as of June 12, 2025 (the “Purchase Agreement”). （纳斯达克：BNTX，“BioNTech”）今天宣布已开始其针对CureVac N.V.（纳斯达克：CVAC，“CureVac”）所有流通股的公开要约交换（“要约”）。该要约是根据BioNTech与CureVac于2025年6月12日签署的购买协议（“购买协议”）进行的。Upon closing, the transaction will bring together two pioneers in mRNA science with complementary capabilities and technologies to advance the development of innovative and transformative investigational mRNA-based cancer immunotherapies for patients in need.. 交易完成后，将汇集两位在mRNA科学领域的先驱者，结合双方互补的能力和技术，推动创新和变革性基于mRNA的癌症免疫疗法的开发，造福有需要的患者。With the acquisition, BioNTech aims to strengthen its research, development, manufacturing, and commercialization capabilities, complementing its expertise in mRNA design, delivery formulations, and mRNA manufacturing. The transaction marks a milestone in the execution of BioNTech’s oncology strategy, which focuses on two pan-tumor programs: mRNA-based cancer immunotherapy candidates, and pumitamig (BNT327), a PD-L1xVEGF-A bispecific antibody candidate. 通过此次收购，BioNTech旨在加强其研发、生产及商业化能力，以补充其在mRNA设计、递送配方和mRNA制造方面的专业优势。该交易标志着BioNTech在执行其肿瘤学战略上迈出了重要一步，该战略聚焦于两大泛肿瘤项目：基于mRNA的癌症免疫治疗候选药物，以及pumitamig（BNT327），一种PD-L1xVEGF-A双特异性抗体候选药物。BioNTech’s all-stock acquisition of CureVac is expected to create long-term value for shareholders of both companies, building on BioNTech’s proven track record in mRNA research, development, manufacturing, and commercialization.. BioNTech 全股票收购 CureVac 预计将为两家公司的股东创造长期价值，此举基于 BioNTech 在 mRNA 研究、开发、制造和商业化方面的可靠业绩记录。Under the terms of the Purchase Agreement, each CureVac share will be exchanged for approximately $5.46 in BioNTech American Depositary Shares (“ADSs”), resulting in an implied aggregate equity value for CureVac of approximately $1.25 billion (subject to the adjustments described below). The consideration is subject to a collar mechanism, such that if the 10-day volume weighted average price of a BioNTech ADS ending on, and including, the fifth business day prior to the closing of the Offer (“VWAP”) is greater than or equal to $126.55, each CureVac share will be exchanged (the “Exchange Ratio”) for 0.04318 of a BioNTech ADS, and if the VWAP is less than or equal to $84.37, the Exchange Ratio will be 0.06476 of a BioNTech ADS. 根据《购买协议》的条款，每股CureVac股份将被换成约5.46美元的BioNTech美国存托股份（“ADS”），从而使CureVac的隐含总股权价值达到约12.5亿美元（需进行下述调整）。对价受制于一个区间机制，即如果截至且包含要约结束前第五个交易日为止的BioNTech ADS的10日成交量加权平均价格（“VWAP”）大于或等于126.55美元，则每股CureVac股份将被换成0.04318股BioNTech ADS（“交换比例”）；如果VWAP小于或等于84.37美元，则交换比例为0.06476股BioNTech ADS。For the duration of the Offer, an indicative Exchange Ratio will be available at . 在要约期间，指示性交换比率将在以下位置提供。www.envisionreports.com/CureVacOffer www.envisionreports.com/CureVacOffer. 。CureVac shareholders who want to participate in the Offer should contact their broker, dealer, or other nominee through which they hold their CureVac shares for further information. Any CureVac shareholder who has any questions, including regarding how to participate, may reach out to the information agent for the Offer, Georgeson LLC, at +1 888 686 7195 (toll free in the US), +1 732 353 1948 (collect) or . 希望参与本次要约的CureVac股东应联系持有其CureVac股份的经纪人、交易商或其他指定人以获取更多信息。任何有疑问的CureVac股东，包括如何参与的问题，可以联系要约的信息代理Georgeson LLC，电话：+1 888 686 7195（美国免费），+1 732 353 1948（收费）。Curevacoffer@georgeson.com Curevacoffer@georgeson.com. 。The Offer will expire at 9:00 a.m. (New York City time) on December 3, 2025, unless extended or terminated earlier, in each case in accordance with the terms of the Purchase Agreement. The Offer is subject to various conditions, including at least 80% of CureVac’s shares (threshold may be reduced to 75% unilaterally by BioNTech under certain circumstances) being tendered into the Offer and accepted for payment and the receipt of required regulatory approvals. 该要约将于2025年12月3日上午9:00（纽约时间）到期，除非根据购买协议的条款提前延长或终止。该要约受多种条件限制，包括至少80%的CureVac股份（在某些情况下，BioNTech可单方面将门槛降低至75%）被提交要约并接受付款，以及获得所需的监管批准。. 。As promptly as practicable following the expiration of the Offer, including the contemplated subsequent offering period, BioNTech and CureVac will effectuate a corporate reorganization of CureVac and its subsidiaries, resulting in BioNTech owning 100% of CureVac’s business. As part of this corporate reorganization, any holders of CureVac shares who do not participate in the Offer will receive the same consideration as they would have received had they participated in the Offer; however, BioNTech ADSs (and cash in lieu of fractional BioNTech ADSs) received pursuant to such reorganization may be subject to Dutch dividend withholding tax at a rate of 15%. 在要约期限届满后（包括预期的后续要约期）尽快，BioNTech 和 CureVac 将对 CureVac 及其子公司进行公司重组，从而使 BioNTech 拥有 CureVac 的全部业务。作为公司重组的一部分，任何未参与要约的 CureVac 股东将获得与他们参与要约所能获得的相同对价；但是，根据该重组收到的 BioNTech 美国存托股份（以及代替零碎 BioNTech 美国存托股份支付的现金）可能需要缴纳 15% 的荷兰股息预扣税。The exchange agent may withhold and sell BioNTech ADSs to satisfy any such withholding tax.. 交易所代理可能会扣留并出售BioNTech的美国存托股份（ADS），以满足任何此类预扣税的要求。In connection with the commencement of the Offer, CureVac will convene an extraordinary general meeting of shareholders (the “EGM”) to be held on November 25, 2025. The EGM will be called to vote on certain resolutions by the CureVac shareholders relating to the proposed transaction with BioNTech, including the post-offer corporate reorganization of CureVac and its subsidiaries, and the appointment of new members to the management and supervisory boards, each as further to be set out in the agenda and explanatory notes that will be made available to CureVac’s shareholders. 鉴于要约的开始，CureVac将召开一次特别股东大会（“特别股东大会”），计划于2025年11月25日举行。特别股东大会将就CureVac股东关于与BioNTech拟议交易的相关决议进行投票，其中包括CureVac及其子公司的要约后公司重组，以及新成员任命至管理层和监事会，具体内容将在提供给CureVac股东的议程和说明文件中进一步列明。The convening notice, agenda, explanatory notes, and other relevant materials for the EGM will be made available free of charge at CureVac’s registered office and on its website (. 本次特别股东大会的召集通知、议程、说明文件及其他相关材料将免费在CureVac的注册办事处及其网站上提供。http://www.curevac.com http://www.curevac.com). The registration date for CureVac shareholders is October 28, 2025.  CureVac shareholders will be able to attend and vote at the EGM, either in person or by proxy, subject to the procedures set forth in the convening notice, in particular complying with the notification cut-off date on November 20, 2025. ). CureVac股东的登记日期为2025年10月28日。CureVac股东将能够亲自或通过代理人出席并投票表决，但需遵守召集通知中规定的程序，特别是2025年11月20日的通知截止日期。The adoption of the proposed resolutions relating to the post-offer reorganization and the post-closing composition of the management and supervisory boards at the EGM is a condition to the expiration of the Offer.  . 与会股东在特别股东大会上通过有关要约收购后重组及收购完成后管理董事会和监事会构成的拟议决议，是本次要约收购期满的条件之一。Should you need help or have questions relating to the EGM and to vote your shares, please contact CureVac’s information agent, Sodali, at 如果您需要帮助或对EGM和投票您的股份有疑问，请联系CureVac的信息代理Sodali，地址是CureVac-EGM@investor.sodali.com CureVac-EGM@investor.sodali.comor +49 69 95179985. 或 +49 69 95179985。BioNTech has filed a registration statement on Form F-4 and amendments thereto (the “Registration Statement”) with the U.S. Securities and Exchange Commission (the “SEC”), which has not yet become effective. BioNTech has filed with the SEC a Tender Offer Statement on Schedule TO, including as exhibits an offer to exchange/prospectus and letter of transmittal, which include the terms of the Offer. BioNTech 已向美国证券交易委员会（“SEC”）提交了 F-4 表格的注册声明及其修订（“注册声明”），但尚未生效。BioNTech 已向 SEC 提交了 TO 表格的要约收购声明，其中包括作为附件的交换要约/招股说明书和转交信函，这些文件包含了要约的条款。Additionally, CureVac has filed a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC containing the recommendation of its management board and supervisory board that CureVac shareholders tender their shares into the Offer. The Schedule TO, Registration Statement, Schedule 14D-9, their exhibits and other Offer materials can be obtained free of charge at the website maintained by the SEC at . 此外，CureVac已向美国证券交易委员会（SEC）提交了Schedule 14D-9表格的征集/建议声明，其中包含其管理董事会和监事会建议CureVac股东将其股份出售给要约方的内容。Schedule TO、注册声明、Schedule 14D-9及其附件和其他要约材料可在美国证券交易委员会（SEC）维护的网站上免费获取。www.sec.gov www.sec.govor by contacting Georgeson LLC, the information agent for the Offer, as set out above. 或通过联系上述要约的信息代理Georgeson LLC。About BioNTech 关于BioNTechBiopharmaceutical New Technologies (BioNTech) is a global next generation immunotherapy company pioneering novel investigative therapies for cancer and other serious diseases. BioNTech exploits a wide array of computational discovery and therapeutic modalities with the intent of rapid development of novel biopharmaceuticals. 生物制药新技术公司（BioNTech）是一家全球下一代免疫治疗公司，率先开发用于癌症和其他严重疾病的新研究疗法。BioNTech利用广泛的计算发现和治疗模式，旨在快速开发新型生物制药。Its diversified portfolio of oncology product candidates aiming to address the full continuum of cancer includes mRNA cancer immunotherapies, next-generation immunomodulators and targeted therapies such as antibody-drug conjugates (ADCs) and innovative chimeric antigen receptor (CAR) T cell therapies. 其多样化的肿瘤学产品候选组合旨在应对癌症的整个连续过程，包括mRNA癌症免疫疗法、下一代免疫调节剂和靶向疗法，例如抗体药物偶联物（ADC）和创新的嵌合抗原受体（CAR）T细胞疗法。Based on its deep expertise in mRNA development and in-house manufacturing capabilities, BioNTech and its collaborators are researching and developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global and specialized pharmaceutical collaborators, including Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, Genevant, Genmab, MediLink, OncoC4, Pfizer and Regeneron.. 基于其在mRNA开发方面的深厚专业知识和内部生产能力，BioNTech及其合作伙伴正在研究和开发多种针对不同传染病的mRNA疫苗候选产品，同时推进其多样化的肿瘤学管线。BioNTech与多家全球性和专业性制药合作伙伴建立了广泛的合作关系，包括百时美施贵宝、Duality Biologics、复星医药、罗氏集团成员基因泰克、Genevant、Genmab、MediLink、OncoC4、辉瑞和再生元。For more information, please visit 更多信息，请访问www.BioNTech.com www.BioNTech.com. 。About CureVac 关于CureVacCureVac (Nasdaq: CVAC) is a pioneering multinational biotech company founded in 2000 to advance the field of messenger RNA (mRNA) technology for application in human medicine. CureVac’s mRNA platform incorporates a series of novel technologies, designed to improve the efficacy, safety and cost-effectiveness of mRNA therapeutics aimed at resulting in enhanced immune responses at lower doses. CureVac（纳斯达克股票代码：CVAC）是一家开创性的跨国生物技术公司，成立于2000年，致力于推进信使RNA（mRNA）技术在人类医学中的应用。CureVac的mRNA平台融合了一系列新颖的技术，旨在提高mRNA治疗药物的有效性、安全性和成本效益，从而以较低剂量实现更强的免疫反应。Additionally, CureVac has developed LNPs, which have been optimized for indication specific use across infectious diseases and oncology. CureVac is leveraging mRNA technology, combined with advanced omics and computational tools, to design and develop off-the-shelf and personalized cancer vaccine product candidates. 此外，CureVac 开发了脂质纳米颗粒（LNPs），这些颗粒已经针对传染性疾病和肿瘤学中的特定适应症进行了优化。CureVac 正在利用 mRNA 技术，结合先进的组学和计算工具，设计和开发现成的和个性化的癌症疫苗候选产品。It also develops programs in prophylactic vaccines and in treatments that aim to enable the human body to produce its own therapeutic proteins. Headquartered in Tübingen, Germany, CureVac also operates sites in the Netherlands, Belgium, Switzerland, and the U.S. . 它还开发预防性疫苗和旨在使人体能够产生自身治疗性蛋白质的治疗方法的项目。总部位于德国图宾根的CureVac还在荷兰、比利时、瑞士和美国设有分支机构。Further information can be found at 更多信息可以在这里找到www.CureVac.com www.CureVac.com. 。Cautionary Statement Regarding Forward-Looking Statements 关于前瞻性陈述的谨慎声明This document includes “forward-looking statements.” Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “look forward,” “investigational,” “pipeline,” “to acquire,” “development,” “to include,” “commitment,” or similar terms. 本文件包含“前瞻性声明”。前瞻性声明通常可以通过诸如“潜在”、“能够”、“将”、“计划”、“可能”、“可以”、“会”、“预期”、“期待”、“研究性”、“管线”、“收购”、“开发”、“包括”、“承诺”或类似词语来识别。Such forward-looking statements include, but are not limited to, statements relating to the ability of BioNTech and CureVac to complete the  Offer and other transactions contemplated by the Purchase Agreement (including the parties’ ability to satisfy the conditions to the consummation of the Offer contemplated thereby and the other conditions set forth in the Purchase Agreement), the expected timetable for completing the transactions, the benefits sought to be achieved in the proposed transactions, the potential and capacity of BioNTech following the transaction, and the potential effects of the proposed transactions on BioNTech and CureVac. 此类前瞻性声明包括但不限于与BioNTech和CureVac完成要约及购买协议中设想的其他交易的能力相关的声明（包括各方完成该要约的能力以及购买协议中规定的其他条件），完成交易的预期时间表，拟议交易寻求实现的利益，交易后BioNTech的潜力与能力，以及拟议交易对BioNTech和CureVac的潜在影响。Many of these risks and uncertainties are beyond the control of BioNTech or CureVac. Investors are cautioned that any such forward-looking statements are based on BioNTech’s or CureVac’s current beliefs and expectations regarding future events and are not guarantees of future performance and involve risks and uncertainties. 许多此类风险和不确定性是 BioNTech 或 CureVac 无法控制的。投资者应注意，任何此类前瞻性陈述均基于 BioNTech 或 CureVac 对未来事件的当前信念和预期，并非对未来业绩的保证，且涉及风险和不确定性。There can be no guarantees that the conditions to the closing of the transactions will be satisfied on the expected timetable or at all. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. 无法保证交易完成的条件会按预期时间表或完全得到满足。如果基本假设被证明不准确，或者风险或不确定性成为现实，实际结果可能与前瞻性陈述中所述的结果存在重大差异。You should not place undue reliance on these statements. . 您不应过度依赖这些陈述。Risks and uncertainties include, but are not limited to, uncertainties as to the timing of the Offer and the subsequent corporate reorganization of CureVac; uncertainties as to how many of CureVac’s shareholders will tender their shares in the Offer; the risk that competing offers or acquisition proposals will be made; the possibility that various conditions to the consummation of the Offer and the transactions contemplated by the Purchase Agreement may not be satisfied or waived; the possibility of a termination of the Purchase Agreement; the ability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing; the effects of disruption from the transactions contemplated by the Purchase Agreement and the impact of the announcement and pendency of the transactions on BioNTech’s and/or CureVac’s business, including their relationships with employees, business partners or governmental entities; the risk that the Offer or the other transactions contemplated by the Purchase Agreement may be more expensive to complete than anticipated; the risk that litigation in connection with the Offer or the other transactions contemplated by the Purchase Agreement may result in significant costs of defense, indemnification and liability; a diversion of management’s attention from ongoing business operations and opportunities as a result of the Offer, the other transactions contemplated by the Purchase Agreement or otherwise; general industry conditions and competition; general political, economic and business conditions, including interest rate, inflation, tariff and currency exchange rate fluctuations, and the ongoing Russia-Ukraine and Middle East conflicts; the impact of regulatory developments and changes in the United States, Europe and c. 风险和不确定性包括但不限于： CureVac要约收购及其后续公司重组的时间不确定性； CureVac股东在要约中出售股份的数量不确定； 可能出现竞争性要约或收购提议； 要约及相关购买协议项下交易完成的各类条件可能无法满足或获得豁免； 购买协议可能终止； 无法取得必要的监管批准，或无法在可接受的条款或预期时间内取得这些批准； 购买协议项下交易所引发的业务中断影响，以及要约及相关交易公告和悬而未决对BioNTech和/或CureVac业务的影响，包括其与员工、商业伙伴或政府实体的关系； 要约或购买协议项下的其他交易完成成本可能高于预期； 与要约或购买协议项下其他交易相关的诉讼可能导致高额的辩护、赔偿及责任成本； 管理层因要约、购买协议项下的其他交易或其他原因而分散对日常业务运营和机会的关注； 行业总体状况及竞争； 总体政治、经济和商业环境，包括利率、通胀、关税和汇率波动，以及持续的俄乌冲突和中东冲突； 美国、欧洲及其他地区监管发展和变化的影响。Neither BioNTech nor CureVac undertakes any obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by law. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in BioNTech’s and CureVac’s respective Annual Report on Form 20-F for the year ended December 31, 2024, in each case as amended by any subsequent filings made with the SEC, available on the SEC’s website at . BioNTech 和 CureVac 均不承担任何公开更新任何前瞻性声明的义务，无论是否由于新信息、未来事件或其他原因，除非法律要求。可能导致结果与前瞻性声明中所述内容存在重大差异的其他因素，可以在 BioNTech 和 CureVac 分别截至 2024 年 12 月 31 日的年度报告 Form 20-F 中找到，每份报告均已通过其后向美国证券交易委员会（SEC）提交的任何修订文件更新，可在美国证券交易委员会的网站上查阅。www.sec.gov www.sec.gov. 。Notice to Investors and Security Holders 投资者和证券持有人通知This document is for information purposes only and does not constitute an offer to sell or the solicitation of an offer to buy any securities nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. 本文件仅供参考，不构成出售任何证券的要约或购买证券的要约邀请，也不应在任何司法管辖区中，在未根据该司法管辖区的证券法进行注册或资格认证之前，进行此类要约、邀请或证券销售，因为这将是违法的。In connection with the Offer, BioNTech has filed a Registration Statement on Form F-4 and amendments thereto (as so amended, the “Registration Statement”) with the SEC, including an offer to exchange/prospectus (the “Exchange Offer Prospectus”), to register under the Securities Act of 1933, as amended, the issuance of BioNTech ADSs. 与此要约相关，BioNTech已向美国证券交易委员会（SEC）提交了F-4表格的注册声明及其修订版（经如此修订的“注册声明”），其中包括交换要约/招股说明书（“交换要约招股说明书”），以根据经修订的1933年《证券法》注册BioNTech ADSs的发行。Such Registration Statement has not yet been declared effective by the SEC. In addition, BioNTech has filed with the SEC a tender offer statement on Schedule TO (the “Schedule TO”), which includes, as exhibits, the Exchange Offer Prospectus, a form of letter of transmittal, and other customary ancillary documents and CureVac has filed with the SEC a solicitation/recommendation statement on Schedule 14D-9 (the “Schedule 14D-9”). 该注册声明尚未被美国证券交易委员会宣布生效。此外，BioNTech已向美国证券交易委员会提交了附表TO的要约收购声明（“附表TO”），其中包括作为附件的交换要约说明书、转送函样本及其他惯例辅助文件，CureVac亦已向美国证券交易委员会提交了附表14D-9的征求/建议声明（“附表14D-9”）。The Offer has commenced. The solicitation and offer to exchange CureVac Shares is being made only pursuant to the Schedule TO and related Exchange Offer Prospectus or the EU Prospectus or the UK exemption document (each as referred to below). This material is not a substitute for the Exchange Offer Prospectus, the Schedule TO, the Schedule 14D-9, the Registration Statement or for any other document that BioNTech or CureVac has filed or may file with the SEC and has sent or will send to CureVac’s shareholders in connection with the proposed transactions.. 要约已经开始。仅根据时间表TO及相关交换要约招股说明书或欧盟招股说明书或英国豁免文件（如下所述）进行征求和提供交换CureVac股份。本材料不能替代交换要约招股说明书、时间表TO、时间表14D-9、注册声明或BioNTech或CureVac已提交或可能提交给美国证券交易委员会并已发送或将发送给CureVac股东的任何其他文件，这些文件与拟议交易相关。BEFORE MAKING ANY INVESTMENT DECISION OR DECISION WITH RESPECT TO THE OFFER, WE URGE INVESTORS OF CUREVAC TO READ THE REGISTRATION STATEMENT, EXCHANGE OFFER PROSPECTUS, SCHEDULE TO (INCLUDING THE EXCHANGE OFFER PROSPECTUS, RELATED LETTER OF TRANSMITTAL, AND OTHER OFFER DOCUMENTS) AND SCHEDULE 14D-9, THE EU PROSPECTUS (IF RELEVANT), THE UK EXEMPTION DOCUMENT (IF RELEVANT), AS EACH MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME, AND OTHER RELEVANT DOCUMENTS CAREFULLY BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT BIONTECH, CUREVAC AND THE PROPOSED TRANSACTIONS THAT HOLDERS SHOULD CONSIDER.. 在就投资决策或与要约有关的决策作出任何决定之前，我们敦促CureVac的投资者仔细阅读注册声明、交换要约招股说明书、Schedule TO（包括交换要约招股说明书、相关转交函及其他要约文件）和Schedule 14D-9、欧盟招股说明书（如适用）、英国豁免文件（如适用），因为这些文件可能不时被修订或补充，并包含有关BioNTech、CureVac及拟议交易的重要信息，持有人应予以考虑。Investors can obtain free copies of the Registration Statement, Exchange Offer Prospectus, Schedule TO and Schedule 14D-9, as each may be amended from time to time, and other relevant documents filed by BioNTech and CureVac with the SEC at 投资者可以在以下网址免费获取BioNTech和CureVac向美国证券交易委员会（SEC）提交的注册声明、交换要约招股说明书、附表TO及附表14D-9（每项文件可能会不时修订）以及其他相关文件：http://www.sec.gov http://www.sec.gov, the SEC’s website, or free of charge from BioNTech’s website ( ，美国证券交易委员会的网站，或者免费从BioNTech的网站获取 (https://www.biontech.com https://www.biontech.com) or by contacting BioNTech’s Investor Relations Department at ）或通过联系BioNTech的投资者关系部门Investors@biontech.de 投资者@biontech.de. These documents are also available free of charge from CureVac’s website ( 这些文件也可以从CureVac的网站免费获取（https://www.curevac.com https://www.curevac.com) or by contacting CureVac’s Investor Relations Department at ）或通过联系CureVac的投资者关系部门communications@curevac.com communications@curevac.com. All documents are also available from Georgeson, LLC, the information agent for the Offer, at +1 888 686-7195 (toll free), +1 732 353-1948 (collect) or 所有文件也可从要约的信息代理机构Georgeson LLC获取，联系电话为+1 888 686-7195（免费电话）、+1 732 353-1948（对方付费）或Curevacoffer@georgeson.com Curevacoffer@georgeson.com. 。EEA 欧洲经济区With respect to the public offering of BioNTech ADSs to the shareholders of CureVac in Austria, Germany, France, Italy, the Netherlands and Spain, this document is an advertisement for the purposes of Regulation (EU) 2017/1129, as amended (the “Prospectus Regulation”). With respect to the public offering of BioNTech ADSs to shareholders of CureVac in Switzerland, this document constitutes advertising in accordance with article 68 Swiss Financial Services Act of 15 June 2018 (the “FinSA”). 关于在奥地利、德国、法国、意大利、荷兰和西班牙向CureVac的股东公开发售BioNTech美国存托股份（ADS），本文件是根据修订后的《欧盟条例2017/1129》（“招股说明书条例”）发布的广告。关于在瑞士向CureVac的股东公开发售BioNTech ADS，本文件构成符合2018年6月15日《瑞士金融服务法》（“FinSA”）第68条规定的广告。This document does not constitute an offer to purchase any BioNTech ADSs or shares in BioNTech and does not replace the securities prospectus (the “EU Prospectus”) which is be available free of charge, together with the relevant translation(s) of the summary and any supplements thereto, if any, from BioNTech’s website (. 本文档不构成购买任何BioNTech存托股份或BioNTech股票的要约，也不能替代证券招股说明书（“欧盟招股说明书”），该说明书可从BioNTech的网站免费获取，并附有摘要及相关翻译（如有）以及任何补充文件。https://investors.biontech.de/eea-switzerland-disclaimer https://investors.biontech.de/eea-switzerland-disclaimer). The EU Prospectus has been approved by the German Federal Financial Supervisory Authority ( ). 欧盟招股说明书已获德国联邦金融监管局批准 (Bundesanstalt für Finanzdienstleistungsaufsicht 联邦金融监管局) and is, therefore, considered approved in Switzerland by the review body of SIX Exchange Regulation Ltd. pursuant to the FinSA. The approval of the securities prospectus by the German Federal Financial Supervisory Authority ( ）因此，根据《金融服务法》被视为已获瑞士 SIX 交易所监管有限公司审查机构批准。证券招股说明书已获德国联邦金融监管局（Bundesanstalt für Finanzdienstleistungsaufsicht 联邦金融监管局) should not be understood as an endorsement of the investment in any BioNTech ADSs or shares in BioNTech. ）不应被理解为对投资任何BioNTech ADS或BioNTech股份的认可。In relation to each state which is a party to the agreement relating to the European Economic Area (a “Relevant Member State”) the offer to exchange all of the CureVac shares for BioNTech ADSs contemplated by the EU Prospectus is not made in that Relevant Member State, except as set out below. No BioNTech ADSs have been offered or will be offered to the public in a Relevant Member State other than in Austria, Germany, France, Italy, the Netherlands and Spain, in each case based on the EU Prospectus, except that BioNTech ADSs may be offered to the public in a Relevant Member State at any time under the following exemptions under the Prospectus Regulation: (i) to any qualified investor as defined in Article 2 lit. 对于作为与欧洲经济区相关协议的缔约方的每个国家（“相关成员国”），根据欧盟招股说明书计划将所有CureVac股份交换为BioNTech存托凭证（ADS）的要约并未在该相关成员国进行，除非如下所述。除奥地利、德国、法国、意大利、荷兰和西班牙外，任何BioNTech ADS均未也并不会基于欧盟招股说明书向相关成员国的公众提供。但BioNTech ADS可在相关成员国随时根据《招股说明书条例》的以下豁免向公众提供：(i) 向符合《条例》第2条定义的任何合格投资者提供。(e) of the Prospectus Regulation, (ii) to fewer than 150 natural or legal persons (other than qualified investors as defined in Article 2 lit. (e) the Prospectus Regulation), or (iii) in any other circumstances falling within Article 1 para. 4 of the Prospectus Regulation, provided that no such offer (as set forth in clauses (i) to (ii)) of BioNTech ADSs will result in a requirement for the publication by BioNTech of a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation.. 根据《招股说明书条例》第2条第(e)项，（ii）少于150名自然人或法人（不包括《招股说明书条例》第2条第(e)项定义的合格投资者），或（iii）属于《招股说明书条例》第1条第4款规定的任何其他情形，前提是上述(i)至(ii)项所述的BioNTech ADSs的要约不会导致BioNTech根据《招股说明书条例》第3条发布招股说明书的要求，或根据《招股说明书条例》第23条补充招股说明书。In relation to Switzerland, the offer of BioNTech ADSs to the public in Switzerland is based on the EU Prospectus, which is considered to be approved by and has been registered and filed with the review body of SIX Exchange Regulation Ltd., or otherwise under the exemptions specified in the FinSA and the Swiss Financial Services Ordinance of 6 November 2019.. 关于瑞士，BioNTech ADS在瑞士向公众的发售基于欧盟招股说明书，该说明书被视为已获批准，并已注册和提交给SIX交易所监管有限公司的审查机构，或根据《金融服务业法》和2019年11月6日的瑞士金融服务条例中规定的豁免条款进行。Investors in Austria, Germany, France, Italy, the Netherlands and Spain as well as investors in Switzerland should acquire BioNTech ADSs solely on the basis of the EU Prospectus (including the documents incorporated by reference therein and any supplements thereto, if any) relating to the BioNTech ADSs and should read the EU Prospectus (including any documents incorporated by reference therein and any supplements thereto, if any) before making an investment decision in order to fully understand the potential risks and rewards associated with the decision to invest in the BioNTech ADSs. 奥地利、德国、法国、意大利、荷兰和西班牙以及瑞士的投资者应仅基于与BioNTech ADS相关的欧盟招股说明书（包括其中引用的文件及任何补充文件，如有）来购买BioNTech ADS，并应在作出投资决定前阅读该欧盟招股说明书（包括其中引用的任何文件及任何补充文件，如有），以充分了解与投资BioNTech ADS相关的潜在风险和回报。Investment in BioNTech ADSs entails numerous risks, including a total loss of the initial investment.. 投资BioNTech ADSs涉及诸多风险，包括初始投资的全部损失。UK 英国With respect to the public offering of BioNTech ADSs to CureVac shareholders in the United Kingdom (the “UK”), BioNTech has published a UK exemption document for the purposes of the prospectus regulation EU 2017/1129 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended. 关于在英国（“英国”）向CureVac股东公开募售BioNTech美国存托股份（ADS），BioNTech已发布了一份英国豁免文件，以符合《欧盟2017/1129招股说明书条例》的要求，该条例因《2018年欧洲联盟（退出）法案》的修订而成为英国国内法律的一部分。This document does not constitute an offer to purchase any BioNTech ADSs or shares in BioNTech and does not replace the UK exemption document which is available free of charge from BioNTech’s website (. 本文件不构成购买任何BioNTech存托凭证或BioNTech股份的要约，也不能替代可从BioNTech网站免费获取的英国豁免文件 ( 。https://investors.biontech.de/uk-disclaimer https://investors.biontech.de/uk-disclaimer). ）。 Investors in the UK should acquire BioNTech ADSs solely on the basis of the UK exemption document (including the documents incorporated by reference therein and any updates thereto, if any) relating to the BioNTech ADSs and should read the UK exemption document (including the documents incorporated by reference therein and any updates thereto, if any) before making an investment decision in order to fully understand the potential risks and rewards associated with the decision to invest in the BioNTech ADSs. 英国投资者应仅基于与BioNTech ADS相关的英国豁免文件（包括其中引用的文件及任何更新内容，如有）来获取BioNTech ADS，并应在做出投资决定前阅读该英国豁免文件（包括其中引用的文件及任何更新内容，如有），以充分了解与投资BioNTech ADS相关的潜在风险和回报。Investment in BioNTech ADSs entails numerous risks, including a total loss of the initial investment.. 投资BioNTech存托凭证涉及诸多风险，包括初始投资的全部损失。CONTACTS 联系人BioNTech: 生物新技术公司：Investor Relations 投资者关系Douglas Maffei, PhD 道格拉斯·马费伊，博士Investors@BioNTech.de 投资者@BioNTech.deMedia Relations 媒体关系Jasmina Alatovic 贾斯米娜·阿拉托维奇Media@BioNTech.de 媒体@BioNTech.de